Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLIFIED: Mobile Unit Same-day Test and Treat for HIV
NCT05405751Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Fundación SEIMC-GeSIDA. Started Jul 2022; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05405751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405751.